All stock lists
Unlock the score
Immatics N.V. (NASDAQ:IMTX)
DE · Delayed Price · Currency is USD
Healthcare · Biotechnology
7.20-0.11 (-1.50%)
Market cap
$1.08B
Insider Score
Health Score
Analyst consensus
Listed since
Dec 12, 2018
Website
Insider Score
/ 100
IMTX Insider Score
Immatics N.V. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Financial Health Score
Fair
From IMTX’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $41.7M
- Net income
- -$206.5M
- Net margin
- -495.3%
Leverage20 / 20
Little or no net debt.
- Total debt
- $14.6M
- Cash
- $232.4M
- Debt / equity
- 0.04
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $429.0M
- Current liabilities
- $56.9M
- Current ratio
- 7.54
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$206.3M
- Free cash flow
- -$210.0M
- FCF margin
- -503.4%
Dilution & runway8 / 20
Some dilution over the past year.
- Shares outstanding
- 136.7M
- Share growth (1y)
- 12.4%
- Cash runway
- 14 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IMTX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 9.14 M | 7.61 M | 19.76 M | 5.19 M | 4.74 M | 18.58 M |
| Revenue Growth (YoY) | 93.03 % | -59.04 % | -64.87 % | -89.74 % | -74.74 % | -38.61 % |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.14 M | 7.61 M | 19.76 M | 5.19 M | 4.74 M | 18.58 M |
| SG&A Expense | 13.94 M | 14.51 M | 13.66 M | 12.67 M | 12.78 M | 12.07 M |
| R&D Expense | 62.41 M | 59.19 M | 49.64 M | 47.18 M | 45.11 M | 41.91 M |
| Operating Expenses | 76.35 M | 73.68 M | 58.64 M | 59.82 M | 57.86 M | 53.96 M |
| Operating Income | -67.20 M | -66.06 M | -38.88 M | -54.63 M | -53.13 M | -35.37 M |
| Pretax Income | -62.77 M | -57.76 M | -35.56 M | -50.67 M | -71.35 M | -40.85 M |
| Tax Provision | -274.00 K | 52.00 K | 134.00 K | -127.00 K | -1.00 M | -994.00 K |
| Net Income | -62.49 M | -57.81 M | -35.70 M | -50.55 M | -70.35 M | -39.85 M |
| EPS (Basic) | -0.46 | -0.43 | -0.28 | -0.42 | -0.58 | -0.33 |
| EPS (Diluted) | -0.46 | -0.43 | -0.28 | -0.42 | -0.58 | -0.33 |
| Shares Outstanding | 136.68 M | 134.64 M | 126.05 M | 121.56 M | 121.55 M | 121.55 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.